NCT05338515View on ClinicalTrials.gov

A Study of Selpercatinib (LY3527723) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

March 12, 2019

Study Completion Date

March 26, 2019

Conditions

Healthy

Interventions

DRUG

Selpercatinib

Administered orally.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY